HUTCHMED (China) Limited (HCM)

NASDAQ: HCM · Delayed Price · USD
8.91
-1.59 (-15.14%)
At close: May 18, 2022 4:00 PM
9.20
0.29 (3.25%)
Pre-market:May 19, 2022 8:11 AM EDT
Market Cap1.54B
Revenue (ttm)356.13M
Net Income (ttm)-194.65M
Shares Out172.91M
EPS (ttm)-1.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume973,551
Open10.27
Previous Close10.50
Day's Range8.78 - 10.67
52-Week Range8.78 - 43.94
Beta0.62
AnalystsBuy
Price Target32.36 (+263.2%)
Earnings DateMar 3, 2022

About HCM

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointesti...

IndustryPharmaceuticals
CEOChristian Hogg
Employees1,760
Stock ExchangeNASDAQ
Ticker SymbolHCM
Full Company Profile

Financial Performance

In 2021, HCM's revenue was $356.13 million, an increase of 56.21% compared to the previous year's $227.98 million. Losses were -$194.65 million, 54.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for HCM stock is "Buy." The 12-month stock price forecast is 32.36, which is an increase of 263.19% from the latest price.

Price Target
$32.36
(263.19% upside)
Analyst Consensus: Buy
Stock Forecasts

News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HUTCHMED (China) Limited - HCM

New York, New York--(Newsfile Corp. - May 9, 2022) - Pomerantz LLP is investigating claims on behalf of investors of HUTCHMED (China) Limited ("Hutchmed" or the "Company") (NASDAQ: HCM). Such investors ...

1 week ago - Newsfile Corp

HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendoc...

HUTCHMED to hold a conference call at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT HUTCHMED to hold a conference call at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT

2 weeks ago - GlobeNewsWire

7 Biotech Stocks to Buy With Key Catalysts for April

Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies belon...

1 month ago - InvestorPlace

Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework

According to a Bloomberg report, U.S. regulators could reportedly have full access to auditing reports from most of the 200-plus China-based companies listed in New York in mid-2022. In the drafting sta...

Other symbols:BGNECASIZLAB
1 month ago - Benzinga

Update on Status under Holding Foreign Companies Accountable Act

HONG KONG, and SHANGHAI, China and FLORHAM PARK, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; SEHK:13) provides an update on its statu...

1 month ago - GlobeNewsWire

Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs

Weibo Corp (WB), on Wednesday, joined previously identified Chinese stocks that may be delisted from U.S. exchanges. More could follow and Alibaba (BABA) could be in SEC crosshairs too.

1 month ago - InvestorPlace

Dow Jones Newswires: SEC-targeted Chinese companies slump; Yum China warns of 2024 delisting risk

Shares of Chinese companies flagged for possible delisting in the U.S. slid in Hong Kong and Shanghai trading Friday, a move that analysts said highlighted geopolitical tensions but would have little im...

Other symbols:BGNEYUMCZLAB
1 month ago - Market Watch

Which Chinese Stocks Could Get Delisted? 6 Companies to Watch.

Today, news that Weibo has been added to the SEC's list of at-risk companies for delisting has investors selling Chinese stocks in a big way. The post Which Chinese Stocks Could Get Delisted?

Other symbols:ACMRBGNEWBYUMCZLAB
1 month ago - InvestorPlace

Why Chinese Stocks Are Falling Apart; Two Chinese Stocks to Dump Immediately

Even China's most prominent companies were not immune to the sharp falls.

Other symbols:YUMC
1 month ago - The Dog of Wall Street

Why Tesla Stock Slumped With Li Auto, Tencent Music, and Hutchmed

The risks of investing in Chinese stocks are growing.

Other symbols:LITMETSLA
2 months ago - The Motley Fool

What's Going On With Zai Lab, Hutchmed, BeiGene Shares Today

Three of the most major drugmakers with roots in China, Zai Lab Ltd (NASDAQ: ZLAB), BeiGene Ltd (NASDAQ: BGNE), and Hutchmed China Ltd (NASDAQ: HCM), have been flagged by the SEC for failing to comply w...

Other symbols:BGNEZLAB
2 months ago - Benzinga

MarketWatch: U.S.-listed China stocks sink as jitters build about overseas listings

Shares of many U.S.-listed Chinese stocks tumbled Thursday after the Securities and Exchange Commission put out an update about foreign companies using accounting firms or branches that cannot be adequa...

2 months ago - Market Watch

These Chinese stocks are down sharply on Thursday. Here's what could be behind the decline

A 2020 law called the Holding Foreign Companies Accountable Act may be behind the sharp decline in a handful of U.S-traded Chinese stocks.

Other symbols:ACMRYUMCZLAB
2 months ago - CNBC

HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase II...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has received a US$15 million milestone payment from A...

2 months ago - GlobeNewsWire

HUTCHMED announces retirement of CEO and appointment of new CEO

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces:

2 months ago - GlobeNewsWire

HUTCHMED Reports 2021 Full Year Results and Provides Business Updates

Oncology/Immunology revenues up 296% to $119.6 million, due to ELUNATE ® growth and the 2021 launches of SULANDA ® and ORPATHYS ® ;

2 months ago - GlobeNewsWire

HUTCHMED Receives Approval to Commercialize ELUNATE® in Macau

First homegrown innovative medicine approved in Macau based on China clinical data First homegrown innovative medicine approved in Macau based on China clinical data

2 months ago - GlobeNewsWire

HUTCHMED to Announce 2021 Final Results

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year...

3 months ago - GlobeNewsWire

HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid T...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 04, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase Ib/I...

3 months ago - GlobeNewsWire

HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I trial in Chi...

3 months ago - GlobeNewsWire

HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that updated analysis of the ongoing in...

4 months ago - GlobeNewsWire

HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytop...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Center for Drug Evaluation o...

4 months ago - GlobeNewsWire

HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lym...

— HMPL-760 is the eleventh innovative potential oncology drug candidate discovered in-house by HUTCHMED —

4 months ago - GlobeNewsWire

HUTCHMED Included in FTSE Russell Indexes

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 19, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has been included by FTSE ...

4 months ago - GlobeNewsWire

HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meeting

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 14, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces new analyses on the ongoing studie...

5 months ago - GlobeNewsWire